Literature DB >> 2496054

Thermostability of human immunodeficiency virus (HIV-1) in a liquid matrix is far higher than that of an ecotropic murine leukemia virus.

H Yoshikura1.   

Abstract

For prevention of HIV infection, which is fatal to man and has no known remedy, sterilization of contaminated materials is particularly important. Before applying any sterilization procedures, they have to be checked by accurately following the kinetics of plaque reduction. Though this is almost self-evident, such studies have been few. Here, a microplaque assay of HIV is established using HPB-ALL human T-cells immobilized on a poly-L-lysine-coated plastic dish. This assay was used to compare the ultraviolet and heat inactivation kinetics of HIV (titrated by this method) with those of Moloney murine leukemia virus (MLV) in a liquid matrix. Though the ultraviolet sensitivities of these viruses were identical (D10 = 2,800 ergs/mm2), HIV was far more resistant to high temperatures (50 degrees C-70 degrees C) than MLV. This implies that these two viruses have different virion structures, though both are members of retroviridae. The higher thermostability of HIV should be taken into account when HIV-contaminated materials are handled.

Entities:  

Mesh:

Year:  1989        PMID: 2496054      PMCID: PMC5917675          DOI: 10.1111/j.1349-7006.1989.tb02235.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  13 in total

1.  Human B cell, T cell and null cell leukaemic cell lines derived from acute lymphoblastic leukaemias.

Authors:  I Miyoshi; S Hiraki; T Tsubota; I Kubonishi; Y Matsuda; T Nakayama; H Kishimoto; I Kimura; H Masuji
Journal:  Nature       Date:  1977-06-30       Impact factor: 49.962

2.  Effect of heat and fresh human serum on the infectivity of human T-cell lymphotropic virus type III evaluated with new bioassay systems.

Authors:  S Harada; H Yoshiyama; N Yamamoto
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

3.  Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers.

Authors:  S H Weiss; J J Goedert; S Gartner; M Popovic; D Waters; P Markham; F di Marzo Veronese; M H Gail; W E Barkley; J Gibbons
Journal:  Science       Date:  1988-01-01       Impact factor: 47.728

4.  Ultraviolet sensitivity of helper function of murine leukemia virus.

Authors:  H Yoshikura
Journal:  Arch Biochem Biophys       Date:  1973-01       Impact factor: 4.013

5.  Transformation of a mouse cell line by murine sarcoma virus (Moloney).

Authors:  H Yoshikura; Y Hirokawa; Y Ikawa; H Sugano
Journal:  Int J Cancer       Date:  1968-11-15       Impact factor: 7.396

6.  Recovery and inactivation of infectious retroviruses from factor VIII concentration.

Authors:  J A Levy; G Mitra; M M Mozen
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

7.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

8.  Evaluation of the safety of blood products with respect to human immunodeficiency virus infection by using an HTLV-I-infected cell line (SKT-1B).

Authors:  A Koito; K Shirono; H Suto; S Matsushita; T Hattori; K Takatsuki
Journal:  Jpn J Cancer Res       Date:  1987-04

9.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.

Authors:  P L Nara; W C Hatch; N M Dunlop; W G Robey; L O Arthur; M A Gonda; P J Fischinger
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

10.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

View more
  6 in total

1.  Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.

Authors:  Tomoko Chiba-Mizutani; Hideka Miura; Masakazu Matsuda; Zene Matsuda; Yoshiyuki Yokomaku; Kosuke Miyauchi; Masako Nishizawa; Naoki Yamamoto; Wataru Sugiura
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

2.  Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons.

Authors:  Y K Shimizu; H Yoshikura
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro.

Authors:  Y K Shimizu; R H Purcell; H Yoshikura
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

4.  Characterization of long-term cultures of hepatitis C virus.

Authors:  N Nakajima; M Hijikata; H Yoshikura; Y K Shimizu
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.

Authors:  Y K Shimizu; M Hijikata; A Iwamoto; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Selective transmission of hepatitis C virus in vivo and in vitro.

Authors:  M Hijikata; K Mizuno; T Rikihisa; Y K Shimizu; A Iwamoto; N Nakajima; H Yoshikura
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.